Document:

EX-10.2

 Certain confidential information contained in this document, marked by [**], has been
omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. 

Exhibit 10.2 
 EXCLUSIVE
LICENCE OF PATENTS AND RESULTS 
 BETWEEN THE UNDERSIGNED, SOPHIA GENETICS SA, a company duly incorporated in accordance with the laws
of Switzerland, under registration number CH-550.1.086.569-3 in the Commercial Register of the Canton of Vaud, domiciled at Rue du Centre 172, 1025 St-Sulpice,
Switzerland, [**], duly authorised for this purpose, hereinafter referred to as the “Company”; 
 AND 

COMUE NORMANDY UNIVERSITY, a national public institution of a scientific, cultural and professional nature, [**], whose statute was approved
by decree no. 2014-1673 of 29 December 2014, represented by its President, [**], hereinafter referred to as “Normandy University”, acting in the name and on behalf of its Normandie Valorisation [Normandy Valuation] [**], [**],
hereinafter referred to as “Normandie Valorisation”; 
 INSERM Transfert SA, Public Limited Company with a
Management Board and Supervisory Board, [**], with its registered offices at [**], [**], represented by [**], acting as delegate of the National Institute of Health and Medical Research (hereinafter, “INSERM Transfert”), a public
scientific and technological establishment, with its registered offices at [**], hereinafter referred to as “INSERM Transfert”; 

THE HENRI BECQUEREL CENTRE, ESPIC [Etablissement de Santé Privé d’Intérêt Collectif (Private Healthcare
Facility of Collective Interest)] Cancer Centre, with its registered offices at [**], [**], [**], hereinafter referred to as “CHB”, acting on behalf of [**], hereinafter referred to as “Laboratory 1”; 

THE UNIVERSITY OF ROUEN NORMANDY, a national public institution of a scientific, cultural and professional nature, with its registered offices
at [**], [**], [**], hereinafter referred to as “UNIROUEN”, acting on behalf of laboratory [**], directed by [**], hereinafter referred to as “Laboratory 2”. 

The CH, INSERM Transfert and UNIROUEN are hereinafter referred to as the “Establishments”. The CHB, INSERM Transfert,
UNIROUEN, Normandy University and the Company may each be referred to hereinafter individually as a “Partner” and collectively as “Partners”. 

[**]. 
 It is, however,
specified that this delegation does not imply the transfer to INSERM Transfert of property rights held or jointly held by INSERM. 
  

 For the execution of this Agreement, INSERM is not considered to be a third party. 

The CHB, INSERM Transfert and UNIROUEN mandate Normandy University via its Normandie Valorisation component to ensure the entire management of
this licence Agreement, in accordance with the stipulations of the mandate commitment between Normandy University and the Establishments. 

In accordance with this mandate, Normandy University is authorised to sign this Agreement in the name and on behalf of the Establishments.

 The Establishments, Normandy University and the Company are hereinafter referred to jointly as the “Parties” and
collectively as the “Party”. 
 WHEREAS, 

Within the framework of research carried out within the Laboratory, [**]; 

The Establishments are the co-owners of [**]; 

The list of elements made available by the Establishments in this context is given in Appendix 1 (integral part of this Agreement); and 

The Company is interested in the aforementioned patent applications and wishes to join forces with the Establishments to validate, through
collaboration, the possibilities for developing and exploiting the technology covered by these patent applications; 
 Consequently, the
Establishments grant the Company an exclusive licence on the patents mentioned above under the terms and conditions defined below. 
 CONSEQUENTLY, IT IS
AGREED AS FOLLOWS: 
 “Affiliates” refers to any legal entity that: 

 

	 	•	 	 directly or indirectly controls the Company; or 

 

	 	•	 	 comes under the same direct or indirect control as the Company; or 

 

	 	•	 	 is controlled directly or indirectly by the Company. 

A legal entity is considered to be controlling another: 

  
 2 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

	 	•	 	 when it directly or indirectly holds more than 50% (fifty percent) of the share capital of that legal entity or
holds more than 50% (fifty percent) of the voting rights of the shareholders or partners of that legal entity; or 

  

	 	•	 	 when it de facto directly or indirectly holds the decision-making power within this legal entity.

 The rights granted to the Affiliates under the terms of this Agreement are only applicable to legal entities that have
the status of Affiliate at the moment when these rights are exercised. If a legal entity loses the status of Affiliate during the term of this Agreement, the rights that legal entity acquired due to its status as an Affiliate shall expire
immediately, unless agreed in writing by the Establishments. Conversely, a legal entity that acquires Affiliate status shall also acquire the rights relating thereto. 

The list of Affiliates is given in Appendix 3, an integral part of this Agreement. 

“Agreement” means this Agreement, in its entirety, including its appendices and any amendments. 

“Business Partners” refers to entities that have a business relationship with the Company for the purpose of executing or
carrying out all or part of the development plan for the Products or allowing them to be used, in accordance with the conditions set out below. 

“Confidential Information” refers to any information transmitted by one of the Parties to the other under this Agreement that
relates to the Field of Use and is designated as confidential during its transmission by making reference in words to this confidentiality. Any confidential information transmitted orally must be confirmed in writing within [**] of its transmission.

 “Date(s) of First Provision” refers to the first time that the Company made the Products available to a third party to
the Agreement. The Date of First Provision will be effective on the day when the Company exceeds the most rapidly reached duration provided for in Section 4.05 of this Agreement. 

“Development Works” refers to all of the works and studies carried out directly by the Company in accordance with the
development plan in Appendix 2 of the Agreement, including all of the works and studies that are necessary for the Company to develop and market the Products directly or indirectly through its Affiliates. 

“Effective Date” refers to the last date on which this Agreement was signed by all the Parties. 

“Field of Use” refers to carcinomas with the exception of the area of use defined in the licence agreement signed between the
Parties on 19 March 2018. 

  
 3 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 “Industrial Property Fees” refers to the direct costs invoiced by the
industrial property firm(s) and by their foreign equivalents for the operations of filing, issuing and maintaining the Patent. Industrial Property Fees do not include any subsequent costs incurred in legal proceedings initiated by one and/or the
other of the Parties to defend the Patent. 
 “Patents” refers to: 

 

	 	•	 	 French patent no. [**] in the names of Establishments, and citing [**] as the inventors thereof;

  

	 	•	 	 the PCT application filed under [**] in the names of the Establishments; and 

 

	 	•	 	 all rights resulting from these applications, including (i) all patents and patent applications, with the
aforementioned French patent application claiming priority elsewhere in the world, (ii) the patents resulting from these applications and (iii) all divisional applications, applications for continuation in whole or in part, re-issues, the reviews, extensions and related rights. 

 A statement of the Patent
portfolio on the date of signature of this Agreement is attached in Appendix 1. 
 The Parties expressly understand that the distribution
and management of property rights relating to patent applications nos. [**] and [**] only concerns the Establishments and they cannot therefore, under any circumstance, dispute the conditions of the Patent’s industrial and commercial use from
which the Company would benefit. 
 An update to Appendix 1 will be carried out as the Agreement is completed. 

“Products” refers to the products that have been developed, manufactured or marketed and that could not be developed, used,
manufactured, marketed or implemented without infringing all or part of the Patent. In the case of returns provided for in Article 5 of this Agreement, the term “Product” is understood to be for a single patient and the same applies for
the duration provided for in Section 4.05 of this Agreement. 
 “Result” refers to the results arising from the
Patent, as well as the technical and scientific knowledge acquired by Laboratories 1 & 2 while executing the various stages of the Patent and that may or may not be protected by an industrial property title. 

“Territory” refers to the countries covered by the Patent. 

“Valid Claim” refers to any claim in an application for a Patent or a Patent in force and not expired, which has not been
withdrawn, cancelled or found to be invalid or unenforceable, by a court or any other competent jurisdiction, by a final ruling and/or a judgement that cannot be appealed. 

Words in the plural may be understood in the singular, and vice versa. 

  
 4 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 1 

PURPOSE, TYPE AND SCOPE OF THE
AGREEMENT 
 Section 1.01. By means of this Agreement, the Establishments grant to the Company, to its Affiliates and to
its Business Partners, which accept, an exclusive licence to the Patents, in order to develop, manufacture and sell Products in the Field of Use and in the Territory (hereinafter the “Licence”). The granting of this licence excludes
any rights to sub-licence. 
 The Company shall not exploit the patents resulting from patent
applications no. [**] and no. [**] outside the Field of Use and the Territory. It is agreed between the Parties that the licence agreement signed between them on 19/03/2018 does not compete with this Agreement. 

It is understood that the Establishments retain the right to use the Patents and Results internally for research and teaching purposes,
excluding any use for commercial purposes in the Field of Use and in the Territory. 
 Section 1.02. The Licence is only granted for
Patents and does not extend to improvements made by one and/or the other of the Establishments to the Patents, nor to countries other than those covered by the Territory. However, the UNIROUEN and the CHB acknowledge that they will make the Patent
updates available to the Company in the Field of Use and in the Territory. 
 ARTICLE 2 

DURATION 
 The
Licence comes into effect on the last date of signature by the Partners and, except in the event of early termination pursuant to the provisions of Article 10 below, will remain in force for one (1) year from the last date of signature by the
Partners and will renew automatically for the duration of the rights attached to the Patent. 
 ARTICLE 3 

TRANSFER OF THE LICENCE AGREEMENT 

Section 3.01. This Agreement is concluded intuitu personae. Consequently, the Agreement is personal, non-assignable and non-transferable. 
 Section 3.02. In the
event of a takeover, merger, absorption, sale or transfer of the Company or its activities, respectively, by, with or to another legal entity, or any other transformation of the Company that may alter the intuitu personae character of this
Agreement (hereinafter referred to as the “Event(s)”), Normandy University via Normandie Valorisation, acting for and on behalf of the Establishments, and the new legal entity will sign this Agreement. 

  
 5 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 The Agreement will only be terminated if Normandy University via Normandie Valorisation,
acting for and on behalf of the Establishments, justifies in writing within [**] of receipt of the notification of the modification by the Company that this modification would adversely affect the protection of the scientific and technical heritage
of the Establishments and/or would be contrary to public order and good morals. In the absence of any notification from Normandy University via Normandie Valorisation, duly substantiated during this period, this Agreement shall rightfully proceed.

 An amendment to this Agreement between the Establishments, Normandy University and said legal entity must be drawn up, simultaneously
with any Event that takes place with the Company. 
 ARTICLE 4 

PRODUCT DEVELOPMENT – OPERATION 

Section 4.01. A development plan (hereinafter referred to as the “Development Plan”) expressing the conditions under
which the Company intends to carry out the Development Works, the provisional timetable for the execution of said Development Works, as well as the date planned for the first launch of the Products onto the market. The Development Plan is described
in Appendix 3 of this Licence. 
 The Company undertakes to inform Normandy University, via Normandie Valorisation, acting on behalf of the
Establishments, of any unforeseen event concerning the said Development Plan which could delay its execution by more than [**]. In such cases, the Company will propose an update of the updated Development Plan corresponding to the development
practices for the sector concerned and free from the technical and/or scientific constraints encountered at the origin of the said delay. 

The new Development Plan must receive the agreement of Normandy University via Normandie Valorisation, said agreement being able to be refused
by Normandy University via Normandie Valorisation only if: 
 (i) the delay results from the financial or strategic decisions
of the Company (such as the internal prioritisation of projects, absence or delay in raising sufficient funds for the execution of the Development Plan); or 

(ii) or if the Development Plan does not conform to development practices in the sector concerned. 

  
 6 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 The Company must provide proof that it has remedied the said delay through said updated
Development Plan in order to promote the development and marketing of the Products. 
 Section 4.02. The Company undertakes to keep
Normandy University via Normandie Valorisation, acting on behalf of the Establishments, informed of the progress of the development of the Products at least [**]. To this end, meetings will be organised at least [**]. These meetings may be held by
telephone or by videoconference and the Company will take written minutes of the same. Normandy University via Normandie Valorisation, will then send these minutes to the Establishments for information purposes. The report will be used for
calculating the invoice that the Company will have to pay. 
 Section 4.03. The Company undertakes to use this Licence and to apply due
diligence to develop, manufacture and sell the Products in the Field of Use and in the Territory. If the Company does not use this Licence within [**] from the Effective Date, this Licence will henceforth be
non-exclusive and Establishments may sign other Licences with third parties in the Field and/or in the Territory. 

Section 4.04. The quality control of the Products and any act relating to the same are under the exclusive responsibility of the Company;
the Establishments will in no way be required to lend their assistance. 
 Section 4.05. The Company is granted the possibility, for a
period of [**] from the last date of signature by the Partners or for [**], the first of the two deadlines being taken into account, of making the Products available free of charge. 

From the First Marketing Date, the Company undertakes to provide and communicate to Normandy University via Normandie Valorisation, within
[**] following the end of the Company’s annual financial year, an annual report justifying the use of Products. 
 The Establishments
may reduce the Territory and/or the Field of Use, by way of an amendment to this Agreement, if the Company has not marketed, nor implemented the steps necessary for the marketing of the Products in the Territory and/or in the Field within a
reasonable time after the end of the development plan, or if the delay in the execution of the development plan exceeds [**]. These steps are described in Appendix 2 attached to this Agreement, entitled “Development Plan”. 

This reduction of the Territory and/or the Domain of the Licence will be the subject of an amendment to this Agreement specifying the new
definition of the Territory and/or the Domain as well as the effective date of the revision. 
 Notwithstanding this reduction in the scope
of the Territory and/or the Domain, the other rights and obligations of the Parties provided for in the Licence will continue as of right. 

  
 7 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 4.06. The Parties shall not under any circumstances disclose the name of the
other Party and/or the Affiliates in advertising or any other promotional material intended for the general or medical public, and shall not use the name of any employee of the other Party and/or Affiliates, nor any product trademark, service mark,
trade name or symbol belonging to a Party or Affiliates of the same, without the Company’s prior written consent (an email will suffice). 

The Establishments undertake not to use the name of the Company, or the name of its employees or of those in whose name it acts. 

Section 4.07. The Company hereby acknowledges that it has the expertise and competences required to use the Patents and Results and to
market the Products. 
 ARTICLE 5 

FINANCIAL TERMS 

Section 5.01. In return for this Licence, the Company and/or its Affiliates must pay Normandy University via Normandie Valorisation,
acting on behalf of the Establishments, the following amounts: 
  

	 	(a)	 Lump sums 

  

	 	•	 	 An initial sum of [**] excluding taxes ([**] excluding tax) on the last date of signature by all the Parties;

  

	 	(b)	 Royalties per analysis 

In return for the rights to use the Patent and the Results that the Establishments grant to the Company (and/or its Affiliates), the Company
will pay Normandy University annually via Normandie Valorisation on behalf of the Establishments: 
  

	 	•	 	 Under direct use: 

A royalty of [**] excluding taxes ([**] excluding tax) for each analysis [**]. 

The fees provided for in this article shall be payable for each country as long as there is a Valid Claim for a Patent in the country
concerned. 
  

	 	•	 	 Under indirect use: 

The same royalty rates will be applied if the Company markets the Products directly or indirectly via its subsidiaries and/or its Business
Partners. 

  
 8 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 5.02. In accordance with the Mandate commitment signed by the Establishments,
Normandy University via its Normandie Valorisation component will recover [**] of the amount due to the Establishments. 
 ARTICLE 6 

MONITORING OF FEES 

Section 6.01. The Company will keep an accurate register of the number of Products that have been distributed under the Agreement and
[**]. 
 The elements of the register will be made available to Normandy University via Normandie Valorisation [**] per year, until the
expiry date of this Agreement extended by [**]. 
 This register will be closed on [**], and the Company will send Normandy University via
Normandie Valorisation, no later than [**] following the year concerned, a detailed statement of sales relating to the Products, broken down by country. 

This statement will show the number of analyses per patient, including the Products used during the period, as well as the related amount in
accordance with the fees per analysis provided for above. 
 This statement of commercial transactions will be sent to the following
address: [**]. 
 Section 6.02. The sums due by the Company and/or its Affiliates and/or its Business Partners in accordance with
Article 5 of this Agreement must be paid within [**] of [**] of issue of an invoice by Normandy University via Normandie Valorisation, acting on behalf of the Establishments, by bank transfer to the following EPSCP Normandy University account: 

Bank code: [**] 
 Counter Code No.
[**] 
 Account No. [**] 
 IBAN
code: [**] 
 SWIFT BIC: [**] 

Section 6.03. Any sum not paid to Normandie University via Normandie Valorisation within the aforementioned deadlines, due to a late
payment, shall give rise to late payment interest calculated at the rate of [**] the legal interest rate in force. In addition, the Company will automatically owe Normandie University via Normandie Valuation a
lump-sum payment for recovery costs of [**] excluding taxes ([**] excluding tax). 

  
 9 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 6.04. The sums owed by the Company to Normandy University via Normandie
Valorisation, acting on behalf of the Establishments by virtue of this Agreement will be paid in euros. 
 Section 6.05. In the event
that no commercial transaction is carried out, the Company must nevertheless send Normandy University via Normandie Valorisation, acting on behalf of the Establishments, a statement certifying the absence of any operation during the year in question
to the address indicated in Section 6.01 of this Agreement, indicating the causes of the absence of sales and the difficulties encountered. 

Section 6.06. The sums received by Normandy University via Normandie Valorisation, on behalf of the Establishments, by virtue of this
Agreement remain in any event definitively and irremediably acquired, and may under no circumstances be returned to the Company. In addition, any sums that remain due from the Company to Normandy University via Normandie Valorisation, on behalf of
the Establishments, upon the expiry or termination date of this Agreement, must be paid to Normandy University via Normandie Valorisation, on behalf of the Establishments. 

Section 6.07. The sums due by the Company to Normandy University via Normandie Valorisation, on behalf of the Establishments, will be
increased by the legal taxes in force, in particular by VAT if applicable. 
 ARTICLE 7 

SECRET 

Section 7.01. Each of the Parties undertakes to keep the Confidential Information secret for the duration of the Agreement and for a
period of [**] after its termination or expiry. 
 Each Party undertakes not to protect in the Field of Use, in any way whatsoever, all or
part of the Confidential Information transmitted by the other Party, in particular by filing a patent application, and not to use them for any purpose other than those set out in Article 1, without the prior written consent of the latter. 

The Parties will ensure that their personnel and any person attached to their service in any capacity whatsoever are also be bound by this
duty of confidentiality. 
 The Parties hereby agree that any disclosure by the Company to a third party of any Confidential Information
related to the invention protected by the Patent will be preceded by the signing of a confidentiality agreement with similar terms and conditions to those of this Article. 

The confidentiality agreements to which the Parties are bound pursuant to this Article shall not apply to information for which the receiving
Party can prove: 

  
 10 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 (a) that it was disclosed to them by mutual agreement between the Parties, or that the
disclosure was previously made by the Owning Party; 
 (b) that they were already in the public domain at the moment they were communicated
by the other Party, or that they entered it after this communication through no fault of the recipient Party; 
 (c) that they were lawfully
received from a third party without breaching the confidentiality obligations contained in this article; 
 (d) that, on the date of their
communication by the owning Party, they were already in its possession; 
 (e) that their disclosure has been imposed by the application of a
mandatory legal or regulatory provision or by the application of a final court decision or an arbitration award. 
 Section 7.02. This
article cannot prevent the Company from sharing documents for the purpose of promoting the marketing of the Products in compliance with the conditions set out in this Agreement. 

ARTICLE 8 
 FILING,
EXTENSION, ISSUE AND MAINTENANCE IN FORCE OF THE PATENTS 

Section 8.01. Normandy University via its component Normandie Valorisation, on behalf of the Establishments, is responsible for the
management of the files, including the follow-up of procedures for the issue and maintenance in force and defence of the Patent, in collaboration with the Establishments. 

Section 8.02. Normandy University via its Normandie Valorisation component shall be liable on behalf of Establishments, to pay any costs
relating to the procedures for obtaining, examining, extending, maintaining in force and defending the Patent in those countries of the Territory where they have been filed or granted, throughout the duration of the Agreement. 

ARTICLE 9 

GUARANTEES 

Section 9.01. The Establishments guarantee the material existence of the Patent and that they are entitled to enter into this Licence
agreement. 
 The Establishments do not give any express or implicit guarantee regarding the suitability of the Patent to achieve any result
whatsoever. 

  
 11 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 The Establishments do not guarantee the granting of Patents that are still under
examination, but shall inform the Company of any adverse development to their being granted. 
 [**]. 

[**]. 
 Section 9.02. The
Company may not call upon the Establishments as a guarantee in the event of damages of any kind whatsoever caused by the Products, the Company being held solely responsible towards its customers and/or any third party for the quality and performance
of Products. 
 Section 9.03. The Company is solely responsible for ensuring that the Products comply with the applicable laws and
regulations. 
 Section 9.04. Notwithstanding any stipulation of this Agreement to the contrary (except for the provisions of
Section 4.03 of this Agreement), the Establishments undertake not to give access to third parties to Patents in the Field of Use without the prior written consent of the Company, and to preserve its exclusivity, as understood in this Agreement.
Similarly, the Establishments undertake to disclose to the Company the existence of any licence relating to Patents conferred by the Establishments on third parties prior to the entry into force of this Agreement. For the sake of clarity, it is
understood that the Parties must obtain the written consent of the Company if they wish to exploit, develop or otherwise use the Patent in the Field of Use, with the exception of the case provided for in Section 1.01 of this Agreement. 

Section 9.05. The stipulations of Article 9 shall remain in force notwithstanding the early termination or expiry of this Agreement. 

ARTICLE 10 

TERMINATION – EXPIRY 

Section 10.01. In the event that the Company ceases all activity, is dissolved, or is subject to amicable or judicial liquidation
proceedings, this Agreement will be automatically terminated. In the event that the Company is the subject of judicial redress proceedings, Normandy University via Normandie Valorisation, acting on behalf of the Establishments, may terminate this
Agreement subject to notifying the Company by registered letter with acknowledgement of receipt. If no response is given within [**] of said notification, this Agreement will be automatically terminated. 

  
 12 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Section 10.02. This Agreement may be automatically terminated by one of the Parties in
the event of non-fulfilment by the other Party of one or more of the obligations contained in its various clauses, and in particular in Article 5 and/or Article 6. This termination will only become effective
three (3) months after the complainant Party has sent a registered letter with acknowledgement of receipt setting out the reasons for the request, unless, within this period, the defaulting Party has fulfilled its obligations or has provided
proof of an impediment resulting from a case of force majeure. The exercise of this right to terminate does not exempt the defaulting Party from fulfilling its contractual obligations until the effective date of the termination, without prejudice to
the payment for damages owed by the defaulting Party in compensation for any damage suffered by the complainant Party as a result of the early termination of this Agreement. 

Section 10.03. This Agreement will also be automatically terminated if the Patent is invalidated in France. 

Section 10.04. If the Company disputes the validity of the Patents or supports Third Parties to contest the patentability or validity of
the rights of the Patents, Normandy University via Normandie Valorisation, acting on behalf of the Establishments, may terminate this Agreement immediately. 

Section 10.05. The Parties have the possibility to terminate the Agreement at any time. Notification of the desire to terminate this
Agreement must take the form of a registered letter with acknowledgement of receipt. The termination will become effective one (1) year after receipt of the registered letter with acknowledgement of receipt. 

Section 10.06. If this Agreement is terminated, the Company shall no longer directly or indirectly use the Patents resulting from patent
applications no. [**] and no. [**] until their expiry. Nothing in this article could prevent the Company from continuing to use the Patents to the extent that they are integrated into Products or services already existing at the moment of the
termination. The stipulations of this licence will continue to apply to such Products, in accordance with the stipulations provided for in Article 11 of the Agreement. 

Section 10.07. In the event of termination, the Establishments will be free to grant to any third party all rights they hold relating to
the Patent, without any obligation towards the Company. 
 ARTICLE 11 

STOCKS 
 If the
Company and/or its Affiliates have Products in stock on the Agreement termination date, they would be authorized to sell these fully-manufactured Products in the Territory for a period of [**] following the date of termination and/or expiry of the
Agreement, subject, on the one hand, to sending a written inventory of stocks to Normandy University via Normandie Valorisation, acting on behalf of the Establishments, on the Agreement termination date and, on the other hand, to respecting the
provisions of Article 5 of this Agreement (Financial conditions). After said period of [**], the Company and/or its Affiliates and/or its distributors and/or its Sub-Licencees will no longer be entitled to
sell any Product. 

  
 13 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 12 

INFRINGEMENT 

Section 12.01. Normandy University via Normandie Valorisation, on behalf of the Establishments and the Company, will inform each other
[**] of any case of infringement by a third party in relation to the Patent of which they are aware and/or any claim or infringement action against them. 

Section 12.02. In the event of an infringement of one or more Patents in the Field of Use by a third party, the Establishments may
initiate legal proceedings against the infringing third party at their own expense, it being understood that the compensation and any damages awarded by the court will be fully and irrevocably acquired. 

This provision shall not prevent the Company from intervening in the proceeding, at its own expense, to obtain compensation for its own
specific damages. SOPHiA GENETICS shall have full and irrevocable entitlement to any compensation and damages awarded to it as a result of such proceedings. 

If the Establishments decide not to initiate any infringement actions and if the Company wishes to act, the Company may, after a formal notice
sent by registered letter with acknowledgement of receipt to Normandy University via Normandie Valorisation on behalf of the Establishments has remained unanswered by the Establishments for more than [**], start a proceeding for infringement at its
sole initiative, in its sole name and at its own expense. In countries where a legal provision prohibits it from initiating a proceeding, the Establishments shall provide, at the Company’s simple request and in a timely manner, all the powers
that are necessary for it to act in the name and stead of the Establishments. 
 Section 12.03. If an infringement lawsuit were brought
against the Company and/or its Affiliates during the use of the Products, due to the use of Patents in the Field, and if following this infringement lawsuit, the Company and/or its Affiliates were condemned, the Company and/or its Affiliates, as the
case may be and in accordance with the provisions relating to Guarantees (Article 9), refrain from calling the Establishments as guarantee. 

[**]. 
 It is agreed between the
Parties that this indemnity clause is intuitu personae. In particular, any claim arising from the indemnity cannot therefore be assigned or transferred to a third party. 

  
 14 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 In the event of a takeover, merger, absorption, sale or transfer of the Company or its
activities, respectively by, with or to another legal entity, or any other transformation of the Company aimed at modifying the intuitu personae character of this clause (hereinafter referred to as the “Event(s)”), this
indemnity clause will fall. 
 In the event that a Transaction occurs between the Company and/or its Affiliates and the third party in
infringement proceedings, this clause will not apply and will be null and void. In the event that compensation has already been paid by Normandy University via Normandie Valorisation, this compensation will be automatically refundable on first
request and will give rise to the application of interest at the legal interest rate. 
 By “transaction” it is understood
to mean any relationship between the Company and the third party in infringement proceedings, such as (without limitation) commercial relationship, shareholder relationship, financing, social etc., for a period of [**] from the date of end of this
Agreement. 
 Section 12.04. If the Patent is cancelled, the provisions relating to guarantees shall apply and may not be waived. 

Section 12.05. The Parties undertake to provide each other with all the documents and elements they may need during the abovementioned
procedures. 
 ARTICLE 13 

ENTIRE AGREEMENT AND LIMITS OF THE
AGREEMENT 
 Section 13.01. This Agreement expresses the entire agreement between the Parties relating to its subject
matter, and replaces and cancels all previous verbal or written agreements relating to said subject matter. No general or specific condition appearing in the documents sent or submitted by the Parties may be incorporated into this Agreement. 

Section 13.02. This Agreement may only be modified or renewed by an addendum signed by the representatives of the Parties, duly
authorised for this purpose. 
 Section 13.03. It is specified that the relations established between the Parties under this Agreement
do not confer any rights other than those mentioned in this Agreement. It is understood that this Agreement does not entail, in particular, the granting to the Company of any right on Patents outside the Field and the Territory. 

Section 13.04. The Agreement must under no circumstances be interpreted as creating a relationship of association or a de facto
partnership between the Parties, each of them being considered as an independent co-contractor. 

Section 13.05. Any public declaration or communication relating to the signing of the Agreement or its content can only be made with the
agreement of the Parties. However, it is agreed that the Company may register the Agreement with the patent offices as stipulated in Article 18 below. 

  
 15 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 14 

TITLES 
 In the
event of any difficulties of interpretation between any clause heading and any of the clauses, the headings will be deemed non-existent. 

ARTICLE 15 

INVALIDITY OF A CLAUSE 

If one or more of the provisions of this Agreement are deemed to be invalid or declared as such in application of a law or regulation—and
in particular European Union law—or following a final decision by a competent court, the other provisions shall remain valid and enforceable and the Parties shall immediately proceed to make the necessary modifications, respecting, as far as
possible, the intent that existed on the date of signing this Agreement. 
 ARTICLE 16 

WAIVER 
 The fact
that one Party does not pursue a breach of any of the obligations under this Agreement by the other Party cannot be interpreted in the future as a waiver of the obligation concerned. 

ARTICLE 17 

DISPUTES – APPLICABLE LAW 

Section 17.01. This Agreement is governed by French laws and regulations. 

Section 17.02. In the event of difficulty regarding the validity, interpretation or performance of this Agreement, the Parties shall
endeavour to resolve their dispute amicably. 
 Section 17.03. In the event of a persistent disagreement, lasting more than [**], from
the first notification concerning the dispute, the dispute will be brought before the competent Courts. 
 Section 17.04. This Article
will remain in force notwithstanding all cases of expiry or termination of this Agreement. 

  
 16 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 18 

REGISTRATION IN THE NATIONAL PATENT REGISTER 

Section 18.01. This Agreement may be entered in the National Patent Register, kept by the National Institute of Industrial Property, and
in the national patent registers, kept by national Industrial Property offices, for the purposes of registering Patents, at the expense of the Company. 

Section 18.02. Any necessary tax registration of this Agreement will be carried out by the Company at its sole expense. 

ARTICLE 19 

NOTIFICATIONS 
 Any
communication or notification under this Agreement must be made by fax or registered mail with acknowledgement of receipt, to the Party concerned at the following address, as long as a change of address has not been notified in writing: 

On behalf of the Establishments: 

[**] 
 [**] 

[**] 
 [**] 

[**] 
 On behalf of the
Company: 
 [**] 
 [**]

 [**] 

  
 17 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 In six (6) original copies. 

 

									
	 On behalf of the COMPANY

 
 [**]

On [HW: 20 May 2019]
	  		  	 On behalf of NORMANDY UNIVERSITY

 
 [**]

On [HW: 27.05.2019]
  

[Stamp: For the President and by delegation,

The General Director of Services

[Signature]

[**]]

					
	 By:
	  	 /s/ on behalf of SOPHiA GENETICS SA
	  		  	 By:
	  	 /s/ on behalf of Normandy University

		  	 Name: [**]
	  		  		  	 Name: [**]

		  	 Title:   [**]
	  		  		  	 Title:   [**]

					
	 By:
	  	 /s/ on behalf of SOPHiA GENETICS SA
	  		  		  	
		  	 Name: [**]
	  		  		  	
		  	 Title:   [**]
	  		  		  	
				
		  		  		  	 NORMANDIE VALORISATION

 
 [**]

On [HW: 29/05/2019]

					
		  		  		  	 By:
	  	 /s/ on behalf of Normandie Valorisation

		  		  		  		  	 Name: [**]

		  		  		  		  	 Title:   [**]

 [Signature Page to Exclusive License Agreement] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 
 SA (SOPHiA) has determined that the
information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or confidential.

 APPENDIX 1: STATEMENT OF PATENTS ON THE EFFECTIVE DATE 

[**] 

  
 19 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 APPENDIX 2: DEVELOPMENT PLAN 

Non-binding Product Development Plan* 

[**] 

  
 20 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 APPENDIX 3: LIST OF AFFILIATES 

[**] 

  
 21 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential.EX-10.3

 Certain confidential information contained in this document, marked by [**], has been
omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential. 

Exhibit 10.3 
 SOFTWARE SUB-LICENCE AGREEMENT TO SOPHIA GENETICS 
 BETWEEN THE UNDERSIGNED, SATT AQUITAINE, Aquitaine
Science Transfert, SAS, SIRET number [**], whose head office is located at [**], hereinafter referred to as “SATT Aquitaine” and SOPHiA GENETICS SA, a company duly incorporated under the laws of Switzerland, bearing
the registration number CH-550.1.086.569-3 in the Commercial Register of the Canton of Vaud, domiciled at Rue du Centre 172, 1025
St-Sulpice, Switzerland, represented by [**], duly authorised for this purpose, hereinafter referred to as “SOPHiA GENETICS”. 

SATT Aquitaine and SOPHiA GENETICS will hereinafter be collectively referred to as the “Parties” and individually as a
“Party”. 
 WHEREAS, 
 [**]
and several researchers from the University of Bordeaux, the CNRS (Centre National de la Recherche Scientifique [French National Centre for Scientific Research]), the Polytechnic Institute of Bordeaux and INRIA (Institut national de recherche en
informatique et en automatique [National Institute for Research in Digital Science and Technology]) have carried out joint work, within the framework of the joint “MONC” (Modélisation en ONCologie [Oncology Modelling]) project team.

 As part of the future investment programme, the SATT Aquitaine project was selected by a decision of the Prime Minister on
19 January 2012. The statutes of SATT Aquitaine were signed on 17 July 2012. The main purpose of SATT Aquitaine (with the designation Aquitaine Science Transfert), is to finance the filing and maintenance of intellectual and industrial
property rights and manage licensing portfolios. 
 In this respect, on 10 April 2015, the SATT Aquitaine Investment Committee studied
the co-maturation project entitled “Nénuphar”, reference “PJ_2014-131”, based on the work of the MONC project team and three (3) software
applications: “Muppet”, developed by [**], “Méta Lung”, developed by [**], and “Cadmos”, developed by [**]. 

This co-maturation project led to the development of two other software applications:
“NENUCORE” and “NOSTRADAMUS” and an updated version of “Cadmos”. 
 In accordance with [**], SATT Aquitaine
has been granted an exclusive licence for the economic rights over the Software Applications. 

 SOPHiA GENETICS is a Swiss company that specialises in artificial intelligence for
data-based medicine and operates the SOPHIA DDM® platform, among other things, and provides integrated diagnostic solutions to healthcare professionals. 

As such, SOPHiA GENETICS has expressed its interest in obtaining from SATT Aquitaine, the concession of a
non-exclusive sub-licence for the Domain, of the economic exploitation rights to the Software Applications, in particular with a view to creating and exploiting
Derivative Software from the source codes of the Software for use on a software platform subject to the terms and conditions set out in that sub-licence. 

The Parties therefore agree to hereby formalise the applicable terms and conditions of the aforementioned
sub-licence. 
 THEREFORE, THE Parties AGREE THE FOLLOWING: 

As used in this Agreement, the following terms shall have the following meanings, provided they are capitalised, whether used in the plural or
in the singular: 
 “Affiliate” shall mean any legal entity that: 

 

	 	•	 	 controls SOPHiA GENETICS, directly or indirectly; or 

 

	 	•	 	 comes under the same direct or indirect control as SOPHiA GENETICS; or 

 

	 	•	 	 is controlled directly or indirectly by SOPHiA GENETICS. 

A legal entity is considered to be controlling another within the meaning of Articles L.233-1 and L233-3 of the French Commercial Code, when it: 
  

	 	•	 	 directly or indirectly owns more than half of the capital of another company; 

 

	 	•	 	 directly or indirectly owns a fraction of the capital conferring on it the majority of voting rights at this
company’s general meetings; 

  

	 	•	 	 effectively determines the decisions in this company’s general meetings due to the voting rights that it
owns; 

  

	 	•	 	 is a partner or shareholder of this company and has the power to appoint or dismiss the majority of the members
of the administrative, management or supervisory bodies of this company. 

 A legal entity is presumed to exercise this
control when it holds, directly or indirectly, more than 50% (fifty percent) of the voting rights and no other partner or shareholder directly or indirectly holds a greater percentage. 

  
 2 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

 treats as private or confidential. 

 The rights granted to Affiliates under the terms of this Agreement are applicable only to
legal entities that have the status of Affiliate at the time of exercise of these rights. In the event that a legal entity loses the status of Affiliate during the term of this Agreement, the rights acquired by this legal entity as a result of its
status as an Affiliate shall expire immediately, unless agreed in writing by SATT Aquitaine. Conversely, a legal entity that becomes an Affiliate shall also acquire the rights relating thereto. 

“Agreement” shall mean the present agreement confirming Maturation Project outcomes, and specifically the non-exclusive sub-licence for the economic rights over the Software Applications. 

“Commercial Intermediaries” shall mean all companies or legal entities and/or all professional individuals, acting
independently, in their own name (such as the broker) or in the name of SOPHiA GENETICS and/or its Affiliates, and on behalf of SOPHiA GENETICS, serving as a commercial intermediary for SOPHiA GENETICS for the marketing of services based on the
Software Applications. 
 “Co-Owners” shall mean the institutions that co-own the Software Applications. These are the University of Bordeaux, Bordeaux INP (National Polytechnic Institute), CNRS, INRIA and Bordeaux University Hospital. 

By “Derivative Software”, we mean all derived or composite works (computer software, software packages and related
documentation), that are based upon the Software Applications, including but not limited to translation, adaptation, arrangement or any other modification of the Software Applications and which include all or some of the lines of Software code. 

Also, within this Agreement, the term Derivative Software shall include all future versions of the Software Application. 

“Domain” shall mean the field of oncology. 

“Effective Date” shall mean the latest signature date of this Agreement by all the Parties. 

“Representative” shall mean the institution designated by the Co-Owners of the
Software, in application of Decree No. 2014-1518, to exercise the rights and obligations set out in Article 2 of the aforementioned text. 

“SATT Licence” shall mean an exclusive licence agreement relating to the maturation results and the Software Applications
granted by the Co-Owners’ Representative to SATT Aquitaine. 

  
 3 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 “Service” shall mean the service provided by SOPHiA GENETICS or SOPHiA
GENETICS Affiliates, or commercial intermediaries on behalf of SOPHiA GENETICS, through the use and operation of all or part of the Software. 

“Software Applications” or “Software” shall mean the executable code and the source code of the following
Software Applications: 
  

	 	•	 	 Cadmos version 1.1 dated 11 March 2017, developed by [**] (CNRS employee), filed with the APP (Agence pour
la Protection de Programmes [Programme Protection Agency]) on 31 March 2017 under reference number [**]; 

  

	 	•	 	 NOSTRADAMUS version 0.1 dated 11 March 2017, which was developed between January 2015 and 11 March 2017
by [**] (CNRS employee), [**] (Bordeaux INP employee), [**] ( University of Bordeaux employee), [**] (INRIA employee) and [**] (Bordeaux University employee); it was filed on behalf and in the names of the CNRS, the University of Bordeaux, Bordeaux
INP and INRIA on 30 March 2017, under reference number [**]; 

  

	 	•	 	 NENUCORE, developed by [**] (Bordeaux University Hospital and the University of Bordeaux employee), [**] (INRIA
employee), [**] (INRIA employee) and [**] (INRIA employee); it was filed on behalf and in the name of the CNRS, the University of Bordeaux, Bordeaux INP and INRIA and the Bordeaux University Hospital, on 30 March 2017, under reference number
[**]. 

 The IDDN certificates for the Software Applications are included in [Appendix 1]. 

“Territory” shall mean the whole world. 

ARTICLE 1 
 PURPOSE,
TYPE AND SCOPE OF THE AGREEMENT 
 By way of this
Agreement, SATT Aquitaine hereby grants SOPHiA GENETICS, who so accepts, a non-exclusive sub-licence for the economic exploitation rights of the Software, in the Domain
and in the Territory through the performance of Services, for the benefit of end customers. 
 The economic exploitation rights granted by
SATT Aquitaine to SOPHiA GENETICS also include the right to use Commercial Intermediaries. 
 The economic rights granted also include the
right of SOPHiA GENETICS Affiliates to perform Services. 

  
 4 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 In the event that SOPHiA GENETICS uses Commercial Intermediaries in application of the
previous paragraph, SOPHiA GENETICS shall be responsible for ensuring that each of the Commercial Intermediaries respects the operating obligations incumbent upon it, in accordance with this Agreement. 

Insofar as this Agreement is a non-exclusive sub-licence, SATT
Aquitaine may only grant non-exclusive sub-licences to third parties in the Domain and in the Territory for the duration hereof. 

SATT Aquitaine and SOPHiA GENETICS also recognise that the Co-Owners retain the right to use the
Software and Derivative Software produced by themselves, individually or in collaboration with third parties, for research purposes in any relevant technical field of application. 

ARTICLE 2 
 ENTRY
INTO FORCE AND DURATION OF THE AGREEMENT 
 This
Agreement shall take effect from the Effective Date and SOPHiA GENETICS may use the Software for a period of fifteen (15) years and shall then cease to have effect, except in the event of early termination in accordance with the provisions of
Article 12 of this Agreement. 
 ARTICLE 3 

TRANSFER OF THE SUB-LICENCE
AGREEMENT 
 Section 3.01. This Agreement is concluded intuitu personae. Consequently, the Agreement is personal,
non-assignable and non-transferable. 
 Section 3.02.
In the event of any change, such as takeover, merger, acquisition, sale or transfer of SOPHiA GENETICS or its activities to another legal entity, thereby modifying the intuitu personae nature hereof (hereinafter referred to as
“Reorganizations”), SOPHiA GENETICS shall inform SATT Aquitaine in writing with acknowledgement of receipt. 

Section 3.03. In the event that the intuitu personae nature hereof should cease to exist, SATT Aquitaine may terminate this
Agreement, on condition that it justifies in writing within [**] from the notification of the Reorganization that the Reorganization of SOPHiA GENETICS would place SATT Aquitaine in a situation of conflict of interest and/or would damage SATT
Aquitaine and/or the Co-Owners, the protection of the scientific and technical potential of the Nation and/or would be contrary to public policy or morality. 

In the event that SATT Aquitaine does not oppose the Reorganization, it is hereby understood that, in any event, the legal entity shall be
subject to the same obligations as those applied to SOPHiA GENETICS under the terms of this Agreement, unless the new Parties agree otherwise. 

  
 5 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 4 

TYPE AND SCOPE OF RIGHTS GRANTED 

Section 4.01. Type and Scope of Rights Granted on the Software. Subject to the fulfilment of the obligations hereof, and in
particular the payment of a fixed fee set out in Article 5 below, SATT Aquitaine hereby grants SOPHiA GENETICS, who so accepts, a non-exclusive sub-licence for the
economic rights listed below, to the Software in the Domain and in the Territory, for the duration of this Agreement. 
 The economic
exploitation rights hereby granted by SATT Aquitaine to SOPHiA GENETICS shall be limited to the following. 
 (a) Right to Reproduction
and Adaptation. 
 The right to reproduction and adaptation includes the following: 

(i) the right to reproduce, digitise and adapt all or part of the Software, individually or collectively with other works, in
all languages and for any country, in any current or future format, known or unknown, intended for any medium and/or method and/or communication network; 

(ii) the right to reproduce or have reproduced, all or part of the Software, individually or collectively, on any magnetic,
optical or other medium, by automatic, analogue, digital, electronic or other means, and on any known or unknown medium, current or future, and in particular, but not limited to CD, DVD, etc. This right includes any reproduction and adaptation
carried out by any known or unknown, current or future process, and in particular any temporary or permanent storage, transmission, uploading or downloading; 

(iii) the right to adapt and develop all or part of the Software, individually or collectively; the right to make new versions
of the Software, or new developments from the Software; the right to modify, arrange, assemble, condense, transcribe, mix, or migrate each element of the Software, individually or collectively, for any users, in any language, on any technical
platform and through any medium and/or means and/or communication network. 
 (iv) The rights listed below authorise SOPHiA
GENETICS to create Derivative Software. 
 (b) Right to Use. 

The right to use includes the following: 

  
 6 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 (i) the right to use all or part of the Software, individually or
collectively, and its adaptations, by any means, in particular but not limited to, the sale or hire for private or public use, in any format, by any process, on any medium, and on any technical platform, known or unknown, current or future,
temporarily or permanently, to any users and through any medium and/or means and/or communication network; 
 (ii) the right
to issue or have issued throughout the world all or part of the reproductions of all or part of the Software, individually or collectively, and of its adaptations for sale, hire or loan for public or private use, and in general, by any means of
communication to users via any medium and/or means and/or communication network. 
 (iii) The right to use shall be
manifested, in particular, by the sale of Services via a platform for end customers. 
 (iv) Notwithstanding the duration of
the Agreement, SOPHiA GENETICS may freely use the Derivative Software that it has produced, at its own risk, for the duration of the copyright protection. 

(c) Right to Representation and Communication. 

The right to representation and communication includes the following: 

(i) the right to represent and have represented all or part of the Software, individually or collectively, and its adaptations
in all languages and in all countries, on any platform and according to any technical standard, current or future, known or unknown; 

(ii) the right to communicate to users all or part of the Software, individually or collectively, or its adaptations by any
process, paid or unpaid, direct or indirect, known or unknown, current or future, by wire or wireless and on any data distribution network, known or unknown, current or future. This right includes, in particular, sharing on any communication
network, via Hertzian waves, cable, satellite, television broadcasting and, in general, by any means, on any network and according to any telecommunication protocol, current or future, known or unknown, including but not limited to GSM, DCS 1800 or
1900, UMTS, Wi-Fi, Wi-Max, Bluetooth, Wap, etc.; 

(iii) the right to distribute all or part of the Software, individually or collectively, on internal or private networks, in
particular companies’ networks, by any person governed by public or private law, free of charge or for payment. 

  
 7 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 (iv) However, moral rights are out of the scope of the sub-licence. The Developers shall retain their moral rights and consequently their ownership must be mentioned. 

Section 4.02. Access to Codes and Technical Assistance. It is understood between the Parties that SATT Aquitaine and the Co-Owners shall not provide any assistance of any kind, particularly technical, with regard to the Software within the scope of this Agreement. 

The Software shall be delivered by post via FedEx to the SOPHiA GENETICS address within a maximum period of [**] from the signing of this
Agreement. 
 A statement signed by the SOPHiA GENETICS contact as indicated in Article 19 shall be drawn up upon delivery of the Software
and shall be sent to Aquitaine Science Transfert (AST). 
 This Agreement gives SOPHiA GENETICS the right to access the Software filed with
the APP. 
 ARTICLE 5 

FINANCIAL TERMS 

In return for the economic exploitation rights of the Software in the Domain and in the Territory, and in particular of the right to create
and use Derived Software, SOPHiA GENETICS shall pay SATT Aquitaine the one-off fee of [**] as of the date of receipt of the FedEx notification by SOPHiA GENETICS of the Software. 

SATT Aquitaine shall issue its invoice in euros in accordance with the applicable legal provisions. 

The sums due to SATT Aquitaine shall be paid in euros. 

The sums due by SATT Aquitaine must be paid within [**] of the date of issue of an invoice by SATT Aquitaine, by bank transfer to the order of
SAS SATT Aquitaine, [**]. 
 Any amounts not paid by SOPHiA GENETICS within the aforementioned deadlines shall result in the application of
late interest payments calculated pro rata temporis at [**] the statutory interest rate in force, without prejudice to SATT Aquitaine’s right to terminate this Agreement in application of Article 12. 

The amounts payable by SOPHiA GENETICS to SATT Aquitaine shall be increased by the statutory taxes in force on the date of their due date, in
particular VAT if applicable. 

  
 8 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Notwithstanding the termination of the Agreement, the amounts received by SATT Aquitaine
under the terms of this Agreement shall remain in any event definitively and irretrievably acquired by SATT Aquitaine and may not under any circumstances be returned to SOPHiA GENETICS. 

In addition, the outstanding amounts payable by SOPHiA GENETICS on the date of expiry or termination of this Agreement must be paid to SATT
Aquitaine. 
 ARTICLE 6 

USE OF DISTINCTIVE MARKS 

Without prejudice to the provisions of the following paragraph, SOPHiA GENETICS shall not, for any purpose whatsoever, including in the
context of non-commercial operations, use the names “National Centre for Scientific Research” or “CNRS”, “University of Bordeaux” or “UBx”, “National Institute for
Research in Digital Science and Technology” or “ INRIA”, “University Hospital Centre” or “CHU” or any brand, name, company name, image, logo, figurative sign or distinctive mark belonging to any of the Co-Owners or any adaptation thereof, including the name of the developers and any of the Co-Owners’ agents, for any public communication, without prior written consent
for each use, from a legal representative who is duly authorised to engage the Co-Owner and/or, where applicable, the individual concerned, in this capacity. 

In order to obtain this agreement, SOPHiA GENETICS shall specifically notify the Co-Owner or
individual person concerned of the transaction affected as well as the form of this representation, its duration and the context in which SOPHiA GENETICS wishes to use the distinctive mark, sign, company name, brand, image, logo or figurative sign
of one or more institutions and/or the individual’s name. 
 In any case, and even if one or more
Co-Owner(S) and/or SATT Aquitaine have given their authorisation for the use proposed by SOPHiA GENETICS, the distinctive marks, signs, company names, brands, images, logos and figurative signs belonging to
one or more Co-Owners or to SATT Aquitaine may not be used by SOPHiA GENETICS in a way which, by virtue of the form and/or the context, can be interpreted as a guarantee granted by the Co-Owners and/or SATT Aquitaine with regards to the Software or any of SOPHiA GENETICS’ products or services whatsoever. 

SOPHiA GENETICS shall ensure that its Commercial Intermediaries and Affiliates are bound by the same obligations. 

For the sole purpose of providing information on the origin of this sub-licence, the words
“Licence relating to intangible assets financed by SATT Aquitaine and INRIA” may appear on any advertising document, technical or explanatory note relating to the Services. SOPHiA GENETICS shall be responsible for ensuring that this
statement, by its form and by the context in which it is placed, cannot be interpreted as any guarantee by SATT Aquitaine concerning the Software and/or Services. 

  
 9 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 7 

CONFIDENTIALITY 

Section 7.01. Each Party shall preserve the confidentiality of the scientific and technical information belonging to each of the Parties
and any information of any nature whatsoever relating to each of the Parties or Co-Owners of which it may become aware during pre-contractual negotiations or during the
execution of this Agreement. 
 Each of the Parties may only publish or communicate all or part of the aforementioned confidential
information to third parties with the written consent of the other Party. Each of the Parties shall inform the other Party or the Co-Owners in advance, by registered letter with acknowledgement of receipt, of
the form and content of the communication or publication. The other Party or the Co-Owners concerned will then have [**] following receipt of the notification to refuse the communication or publication, in the
event that it would cause damage to the interests of one of the other Parties and/or to the protection of scientific and technical potential. In the event that the other Party fails to respond within the aforementioned period, the publication or
communication is deemed to be accepted. 
 In particular, the Parties shall maintain and ensure the maintenance of the confidentiality of
all the knowledge shared with them via the Software, which belongs to the Co-Owners. 

Section 7.02. The Parties shall ensure that their staff and any person attached to their service in any capacity whatsoever shall also be
bound by this duty of confidentiality. 
 Section 7.03. The duties of confidentiality to which the Parties are bound in accordance with
this Article 7 shall not apply to information for which the Parties can prove that: 
 (a) they disclosed it after obtaining the prior
written authorisation of the other Party or the Co-Owners; 
 (b) it belonged in the public domain at
the time of its communication by the other Party or the Co-Owner, or that it entered the public domain after this communication through no fault of the other Party; 

(c) it has been lawfully received from a third party; 

  
 10 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 (d) they were obliged to disclose the information by application of a mandatory legal or
regulatory provision or by the application of a final court decision or an arbitration award. 
 The above exceptions are not cumulative.

 Section 7.04. The Parties shall not file a patent application or other Industrial Property titles including the other Party’s
scientific and technical information, of which it may become aware during pre-contractual negotiations or during the execution of this Agreement, and in particular scientific and technical information about
the Software, without having obtained the prior written authorisation of the other Party or the Co-Owners. 

Section 7.05. This duty of confidentiality shall remain in force for the duration of this Agreement and for [**] after its expiry or its
termination and with regard to expertise until the information enters the public domain. 
 ARTICLE 8 

OWNERSHIP OF SOFTWARE AND DERIVATIVE SOFTWARE 

The Software is the exclusive property of the Co-Owners. 

The licensing does not involve the transfer of any property rights to SOPHiA GENETICS. 

SOPHiA GENETICS shall take all necessary measures to protect the property rights of the Software and to respect the moral rights of the
developers. 
 The Parties shall inform each other of any infringement of rights to the Software of which they are aware. 

Derivative Software produced by SOPHiA GENETICS shall be the property of SOPHiA GENETICS in accordance with Article L.113-4 of the French Intellectual Property Code. Therefore, they shall be free to use it without any other fee than that which has already been paid under Article 5 of this Agreement. 

Derivative Software produced exclusively by one or more Co-Owners shall be the exclusive property of
the Co-Owners concerned in accordance with article L.113-4 of the French Intellectual Property Code. 

  
 11 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 9 

USE 
 SOPHiA
GENETICS shall use the Software effectively, directly and/or indirectly, in the Territory through the provision of Services in the Domain. In addition, SOPHiA GENETICS shall make all reasonable effort that, in its sole discretion, it deems necessary
for the operation of the Services based on the Software. 
 ARTICLE 10 

GUARANTEES 

Section 10.01. The Software Applications are research prototypes. It is therefore the responsibility of SOPHiA GENETICS to ensure that
its technical characteristics and functionalities correspond to its needs. 
 Section 10.02. As a result, SATT Aquitaine grants the
Software “as is” and does not guarantee SOPHiA GENETICS against any faults and operating anomalies thereof. SOPHiA GENETICS agrees to use the Software at its own risk. 

Section 10.03. SOPHiA GENETICS agrees that neither SATT Aquitaine nor the Co-Owners shall be
bound by any guarantee from SOPHiA GENETICS with a view to ensuring the proper functioning or updating or operation of the Software. 

Section 10.04. SOPHiA GENETICS is solely responsible for the development of the Software in order to adapt it to its mode of operation
and to ensure that the Services are in compliance with applicable laws and regulations. 
 Section 10.05. SATT Aquitaine declares that
on the date of the Agreement coming into force it is not aware of any third-party rights that may affect the operation of the Software. 

ARTICLE 11 

INFRINGEMENT 

Section 11.01. SATT Aquitaine and SOPHiA GENETICS shall keep each other fully and rapidly informed of any infringement of which they may
be aware by a third party in relation to the Software. SOPHiA GENETICS must promptly inform SATT Aquitaine of any complaints and infringement actions that may be initiated against SOPHiA GENETICS on the basis of the Software. 

Section 11.02. In the event that infringement proceedings are brought against SOPHiA GENETICS and/or its Commercial Intermediaries and/or
Affiliates during the operation of the Software, SATT Aquitaine shall provide SOPHiA GENETICS with the information at its disposal with a view to the defence of SOPHiA GENETICS or its Commercial Intermediaries and/or Affiliates. 

  
 12 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 In the event that SOPHiA GENETICS were to be convicted as a result of such infringement
proceedings, SOPHiA GENETICS shall exonerate SATT Aquitaine and the Co-Owners. SOPHiA GENETICS shall refrain from impleading SATT Aquitaine and/or the Co-Owners and may
not claim therefrom any compensation, nor reimbursement of any amounts already paid to SATT Aquitaine nor any reduction of amounts outstanding at the time of the ruling of the final court decision. 

SOPHiA GENETICS shall ensure that its Commercial Intermediaries and Affiliates shall be bound by the same terms as those defined herein. 

Section 11.03. In the event of an infringement of all or part of the Software by a third party, SATT Aquitaine may initiate legal
proceedings against the infringing third party at its own expense, it being understood that they shall have full and irrevocable entitlement to any compensation and damages awarded by the court. 

This stipulation shall not prevent SOPHiA GENETICS from intervening in the proceeding, at its own expense, to obtain compensation for its own
specific damages. SOPHiA GENETICS shall have full and irrevocable entitlement to any compensation and damages awarded thereto as a result of such proceedings. 

Section 11.04. Notwithstanding the termination or expiry of this Agreement, the provisions of this Article 11 shall remain in force. 

ARTICLE 12 

TERMINATION – EXPIRY 

Section 12.01. This Agreement will be terminated automatically in the event of cessation of activity, dissolution or voluntary
liquidation of SOPHiA GENETICS. 
 In the event that SOPHiA GENETICS is the subject of judicial reorganisation or liquidation proceedings,
this Agreement shall be automatically terminated after formal notice has been sent to the administrator and remained unanswered for more than [**], subject to the provisions of Articles L. 622-13 and L.641-10 of the French Commercial Code. 
 Section 12.02. This Agreement may be automatically
terminated by either of the Parties in the event of non-performance by the other Party of one or more of the obligations contained in its various clauses, and in particular Article 1 (purpose, type and scope
of the agreement), to Article 4 (Type and scope of the rights granted) and to Article 5 (Financial Terms). This termination shall only take effect [**] has sent a registered letter with acknowledgement of receipt setting out the grounds for the
complaint, unless, 

  
 13 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 
within this period, the defaulting Party has fulfilled its obligations or has provided proof of an impediment resulting from a case of force majeure. The exercise of this right of termination
does not exempt the defaulting Party from fulfilling its contractual obligations until the effective date of the termination, without prejudice to the payment of damages owed by the defaulting Party in compensation for any damage suffered by the
complainant Party as a result of the early termination of this Agreement. 
 In the event of termination for fault, negligence or non-compliance with a provision of this Agreement on the part of SATT Aquitaine, the right to use Derived Software by SOPHiA GENETICS and, in particular, the right to market the Services incorporating the Derivative
Software shall not be restricted in any way. 
 Section 12.03. In the event of termination of this Agreement: 

(a) SOPHiA GENETICS shall not disclose and no longer use or allow all or part of the Software to be used directly or indirectly until the
elements of the Software have clearly entered into the public domain. 
 (b) SOPHiA GENETICS shall return to SATT Aquitaine, [**] following
the expiry or termination of this Agreement, all documents and the various materials relating to the Software that SATT Aquitaine and/or the Co-Owners have forwarded without being able to retain a copy. 

(c) SOPHiA GENETICS shall ensure that its Affiliates are bound by the above obligations. 

Section 12.04. In the event of termination of this Agreement, any agreements concluded with Commercial Intermediaries shall be terminated
automatically on the termination date of this Agreement. 
 ARTICLE 13 

ENTIRE AGREEMENT AND LIMITS OF THE
AGREEMENT 
 Section 13.01. This Agreement together with its appendix defines all the obligations of the Parties with
regard to its subject matter. No general or specific condition contained within documents sent or given by the Parties may be incorporated into this Agreement. 

Section 13.02. This Agreement may only be modified or renewed by an amendment signed by the representatives of the Parties, duly
authorised for this purpose. 
 Section 13.03. It is specified that the relations established between the Parties under this Agreement
do not confer any rights other than those mentioned in this Agreement. 

  
 14 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 14 

TITLES 
 In the
event of any difficulties of interpretation between any clause title and any of the clauses, the titles will be deemed non-existent. 

ARTICLE 15 

UNENFORCEABLE PROVISIONS 

Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction—and in particular, European Union law—or
following a final decision of a competent court, shall be so only to the extent of such prohibition or unenforceability, but all the remaining provisions shall remain valid and enforceable and the Parties shall proceed without delay to the necessary
modifications respecting, as far as possible, the intent that existed at the signature date of this Agreement. 
 ARTICLE 16 

WAIVER 
 The fact
that one Party does not pursue a breach by the other Party of any of the obligations referred to in this Agreement cannot be interpreted in the future as a waiver of the obligation in question. 

ARTICLE 17 

DISPUTES – APPLICABLE LAW 

Section 17.01. This Agreement is governed by French laws and regulations. 

Section 17.02. In the event of difficulty regarding the validity, interpretation or performance of this Agreement, the Parties shall
endeavour to resolve their dispute amicably. 
 Section 17.03. In the event of a persistent disagreement, lasting more than [**], from
the first notification concerning the dispute, the dispute shall be brought before the competent French courts. 
 Section 17.04. This
Article shall remain in force notwithstanding all cases of expiry or termination of this Agreement. 
 ARTICLE 18 

LANGUAGES 
 This
Agreement has been drawn up solely in the French language. 

  
 15 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 ARTICLE 19 

NOTIFICATIONS – INFORMATION 

Any notification required under this Agreement shall be sent by registered post with acknowledgement of receipt, to the relevant Party at the
following address: 
 For SOPHiA GENETICS: 

For the Attention of [**]; Rue du Centre 172, CH-1025,
St-Sulpice, Switzerland—copy to [**] 
 For SATT Aquitaine: 

For the Attention of [**] 

  
 16 

Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 

SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually 

treats as private or confidential. 

 Made in two (2) original copies: one (1) for SATT Aquitaine and one (1) for
SOPHiA GENETICS. 
  

									
	 Signed in TALENCE,
 On
    30.11.2017
	  		  	 Signed in ST SULPICE (Switzerland),

On     30.11.2017

			
	SATT AQUITAINE	  		  	SOPHIA GENETICS SA
					
	By:	  	 /s/ on behalf of SATT Aquitaine
	  		  	By:	  	 /s/ on behalf of SOPHiA GENETICS SA

		  	Name: [**]	  		  		  	Name: [**]
		  	Title:   [**]	  		  		  	Title:   [**]
					
		  	[Seal: AQUITAINE SCIENCE TRANSFERT	  		  	By:	  	 /s/ on behalf of SOPHiA GENETICS SA

		  	 Innovation accelerator
	  		  		  	Name: [**]
		  	 (AT 2017—148 VISA)]
	  		  		  	Title:   [**]

 [Signature Page to Software Sub-License Agreement] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 
 SA (SOPHiA) has determined that the
information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential. 

 APPENDIX 1 

IDDN SOFTWARE CERTIFICATES 

[**] 

  
 Certain confidential
information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS 
 SA (SOPHiA) has determined that the
information (i) is not material and (ii) is the type that SOPHiA customarily and actually 
 treats as private or
confidential.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]